-
Nat Commun: Short H2A histoprotein mutants express and manifest cancer protein properties in cancer
Time of Update: 2021-02-03
B In a variety of cancers, the expression researchers by the species of short H2A sequence and wild H2A cancer protein-related mutations comparative analysis, the researchers found that sH2A protein has similar to the nuclear small body instability associated with the recurrence of cancer gene mutations, that is, with inherent cancer protein characteristics, the most typical sH2A mutation protein is H2A.B.
-
WCLC 2020: Datopotamab deruxtecan and Enhertu show promising clinical activity in patients with advanced non-small cell lung cancer
Time of Update: 2021-02-03
results from the TRTPION-PanTumor01 Phase I trial showed good clinical activity in patients with late-stage or metastasis NSCLC targeting TRAP2.
addition, the results of the DESTINY-Lung01 Phase II clinical trial showed that metastasis NSCLC patients using Enhertu, which targeted HER2, had preliminary evidence of tumor resistance in HER2 over-expression queues.
-
WCLC 2020: Tagrisso significantly extends the disease-free survival of non-small cell lung patients with EGFR mutations
Time of Update: 2021-02-03
results from the ADAURA Phase III clinical trial showed that AstraZeneta's Tagrisso (osimertinib) extended the disease-free survival (DFS) in patients with skin growth factor subject mutation (EGFRm) non-small cell lung cancer (NSCLC).
-
Nature publishes || This study is a landmark advance in human cancer research in the last 20 years!
Time of Update: 2021-02-03
confirmed that tedratic vaccines against HPV 16 and 18 may reduce the risk of cervical cancer; and in 2006, Mercadon developed the first successful HPV vaccine to prevent cervical cancer, Gardasil (for HPV 6, 11, 16 and 18), which was subsequently approved by the U.S. FDA in Europe In 2014 and 2015, the FDA and EMA subsequently approved Gardasil-9, a vaccine that can prevent nine types of HPV infection.
-
NICE recommends Revlimid (lynadamine) for primary treatment of patients with multiple myeloma
Time of Update: 2021-02-03
recommendation was supported by two Phase III clinical data, which showed that Revlimid maintenance therapy significantly improved progressive survival (PFS) in patients with primary multiple myeloma compared to placebo.
-
Nat Commun: Sarcoma classification tool based on DNA methylation analysis
Time of Update: 2021-02-03
previous studies have shown that DNA methylation-based analysis shows the potential for diagnosis of cartilage and osteosarcoma subsypes.
the study, researchers aim to develop a DNA methylation-based classification tool for labeling cartilage and osteosarcoma in various subsypes and age groups.
-
The London Cancer Institute (ICR) :p albociclib is expected to treat triple-negative breast cancer
Time of Update: 2021-02-03
Palbociclib is expected to play a role in triple negative breast cancer (TNBC), according to researchers at the London Cancer Institute (ICR).
ICR researchers have found that TNBC cells with lower CREBBP levels can grow faster.
-
Nat Commun: Nicotine promotes lung metastasis in breast cancer by recruiting N2 neuxual granulocytes
Time of Update: 2021-02-03
nicotine induces neugenic granulocytes to promote the formation of pre-lung ecological levels, epidemiological studies have also shown a significant correlation between smoking/nicotine and increased risk of various cancers.
-
Br J Cancer: Comparative analysis of three tyrosine kinase inhibitors targeted at HER2
Time of Update: 2021-02-03
previous studies have confirmed gene amplification of HER2 and over-expression of proteins in breast and other cancers, and many her2-targeted therapies have been developed and approved.
the new TKI reaction/resistance markers by cross-analyzing the drug response spectrum with mutations, gene copies, and expression data.
-
J Natl Cancer Inst: Global Breast Cancer Treatment Guidelines Summary Analysis | Most guides are not practical!
Time of Update: 2021-02-03
, the analysis included 49 different BC treatment guidelines, most of them in English (n-23), most of which were developed in upper-middle- and high-income countries in Europe and the United States (n-39).
-
Eur J Cancer: The efficacy of BRAF and MEK inhibitors in a combined treatment for patients with advanced melanoma in Asia
Time of Update: 2021-02-03
total prognosis (PFS and OS) collected 144 medical records, and the final analysis included 112, 14 of which were limb end/mucosal melanoma.
, the B-Minh program is effective for patients with melanoma in Japan, including those with limb end/mucosal melanoma.
-
AL101 treats three-negative breast cancer activated by the Notch signaling path
Time of Update: 2021-02-03
Oncology company Ayala Pharmaceuticals announced today that phase II TENACITY clinical trials for patients with the selective small molecule AL101 to treat relapse or metastatic (R/M) triple negative breast cancer (TNBC) activated by the Notch signal path, have been officially launched.
-
J Clin Oncol: The mental health problems of young cancer survivors cannot be ignored!
Time of Update: 2021-02-03
the absolute incidence remains low, there is a significant increase in the risk of serious events associated with mental disorders among cancer survivors.
-
After taking the drug, the tumor enlarges, indicating that the anti-cancer drug is not effective? Professor Wu Yilong: This new standard should be looked at
Time of Update: 2021-02-03
immunotherapy is a "god drug", the combined side effects will be greater CTLA-4 inhibition approved for the market, marking the rise of a new generation of immunotherapy drugs; Immune therapy, represented by PD-1, increased the survival rate of patients with advanced non-small cell lung cancer by less than 5% to 16% in five years, with more and more amazing clinical data, and immunotherapy was thus known as the "anti-cancer drug".
-
WCLC 2020: Patritumab Deruxtecan treats NSCLC patients with EGFR mutations
Time of Update: 2021-02-03
About 25 to 30 percent of lung cancer worldwide has EGFR mutations, and it is estimated that about 83 percent of all NSCLC tumors have high expression of HER3 protein, which may be associated with increased metastasis, reduced survival, and standard drug resistance.
-
WCLC 2020: Neratinib treats metastasis non-small cell lung cancer with EGFR exon 18 mutation, and phase II studies yield relatively positive results
Time of Update: 2021-02-03
Biopharmaceutical company Puma Biotechnology recently published the interim results of a queue of patients with metastasis non-small cell lung cancer (NSCLC) who had previously received EGFR-targeted tyrosine kinase inhibitors (TKI) in the treatment of 18 mutations in the exoskeleton exoskeleton (EGFR).
-
The cancer hospital in the southern suburbs of Beijing resumed treatment on Feb. 2
Time of Update: 2021-02-02
According to the requirements of prevention and control, the relevant medical and security personnel and the overall environment and key parts of the hospital have been nucleic acid testing, the initial test results are negative.
-
Junshi TIGIT single resistance approved clinically
Time of Update: 2021-02-02
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
-
Lancet Gastroenterol Hepatol: Lonsurf in combination with Remo Reeds to treat the efficacy and safety of non-removable advanced stomach cancer
Time of Update: 2021-02-01
In summary, Lonsurf combined with Remo reed monoantigen for patients with advanced gastric cancer treated in the past has certain clinical efficacy, safety is controllable, and is not affected by the past with or without Remo reed monoantigen exposure.
-
Br J Cancer: Systematic therapeutic response and gene expression of plasma cell-like urethroid cancer
Time of Update: 2021-02-01
study aims to explore the efficacy of non-metastasis PUC preoperative platinum chemotherapy and the efficacy of late-stage PUC immuno checkpoint inhibitors (ICIs).
data on non-metastasis PUC and late PUC cases treated with ICI were collected in the previous study population and in the main clinical analysis subgroups.
